-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to the issuance arrangement, this week (March 28-April 1), a total of 9 new shares were declared, namely Guanlong Energy Saving, Puyuan Jingdian, Qifeng Precision Industry, Haichuang Pharmaceutical, Weixin Pharmaceutical Co.
, Ltd.
Jie Chuangxin, Ruide Intelligence, Junxin Co.
, Ltd.
, Jindao Technology, Liansheng Chemical, among which Haichuang Pharmaceutical is a new pharmaceutical stock.
The stock will be issued on March 30 and officially listed on the Science and Technology Innovation Board
.
According to the announcement of the company's recent public offering of shares and its listing on the Science and Technology Innovation Board, CITIC Securities is the company's sponsor (lead underwriter)
.
The estimated total number of shares issued this time is 24.
76 million shares, accounting for approximately 25.
01% of the issuer's total share capital after the issuance
.
Among them, 4.
704 million shares were issued online, accounting for about 20.
00% of the issued amount after deducting the initial strategic placement amount
.
The subscription limit is 4,500 shares, and the top-tier subscription requires a market value of 45,000 yuan
.
Haichuang Pharmaceutical is an innovative drug company focusing on major therapeutic areas such as cancer and metabolic diseases.
It has built a product pipeline covering prostate cancer, hyperuricemia/gout, esophageal cancer, breast cancer and other indications.
Currently, there are 10 There are 4 products under research, of which 4 varieties have entered the clinical trial stage
.
Since Haichuang Pharmaceutical started to focus on the deployment of PROTAC technology as early as 2016, the company has also received high attention from the market recently
.
PROTAC stands for Protein Degradation Targeted Chimera, which uses the ubiquitin-proteasome system to induce targeted protein degradation
.
Compared with traditional inhibitors or targeted drugs, PROTACs have the characteristics of fewer adverse reactions, higher targeting and precision, and can prevent mutation-driven drug resistance of enzyme inhibitors
.
At present, PROTAC has become a major new drug outlet after PD-1 inhibitors and CAR-T.
In this field, domestic and foreign companies continue to enter the market, and R&D enthusiasm is high
.
However, there is currently no PROTAC drug approved for marketing in the world, and only a batch of PROTAC drugs are in the clinical or clinical stage
.
Arvinas' ARV-110 is regarded by the industry as the world's first PROTAC drug that is expected to be approved
.
Throughout the country, the number of pharmaceutical companies in the PORTAC field has grown to dozens, including Haisco, Kintor, Hengrui, BeiGene, Haichuang, and CSPC
.
Among them, the leading clinical progress includes Kintor Pharmaceutical, Haisco, BeiGene, and Haichuang Pharmaceutical
.
It is reported that the three PROTAC drugs of Haichuang Pharmaceutical, AR-PROTAC HP518, AR-sv-PROTAC HC-X029 and SHP2-PROTAC HC-X035, are among the top in clinical progress
.
Among them, HP518 is an oral PROTAC drug for the treatment of prostate cancer that degrades AR, and its in vitro biological activity and efficacy are comparable to Arvinas' ARV-110
.
HC-X035 is the world's first PROTAC drug that targets SHP2 degradation independently developed by Haichuang Pharmaceuticals.
It can specifically bind to SHP2 and induce its degradation, inhibit the formation and growth of tumor cells, and thus achieve the purpose of treating tumors
.
The prospectus shows that since its establishment, Haichuang Pharmaceutical has gradually built and improved four core technology platforms including PROTAC targeted protein degradation technology platform and deuterated drug research and development platform
.
The company plans to publicly issue no more than 24.
76 million shares on the Science and Technology Innovation Board.
The funds raised will be used for innovative drug research and development projects, investment in research and development production base construction projects, and development reserve funds
.
According to the "14th Five-Year Plan for Pharmaceutical Industry Development" jointly issued by nine departments of China in January this year, cutting-edge core technologies and drugs including PROTAC targeted protein degradation technology have been incorporated into the plan
.
The industry predicts that with the help of policies, talents, capital, etc.
, Chinese companies are expected to become strong competitors in this track, and companies that deploy in this track in advance are expected to benefit significantly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, Ltd.
Jie Chuangxin, Ruide Intelligence, Junxin Co.
, Ltd.
, Jindao Technology, Liansheng Chemical, among which Haichuang Pharmaceutical is a new pharmaceutical stock.
The stock will be issued on March 30 and officially listed on the Science and Technology Innovation Board
.
According to the announcement of the company's recent public offering of shares and its listing on the Science and Technology Innovation Board, CITIC Securities is the company's sponsor (lead underwriter)
.
The estimated total number of shares issued this time is 24.
76 million shares, accounting for approximately 25.
01% of the issuer's total share capital after the issuance
.
Among them, 4.
704 million shares were issued online, accounting for about 20.
00% of the issued amount after deducting the initial strategic placement amount
.
The subscription limit is 4,500 shares, and the top-tier subscription requires a market value of 45,000 yuan
.
Haichuang Pharmaceutical is an innovative drug company focusing on major therapeutic areas such as cancer and metabolic diseases.
It has built a product pipeline covering prostate cancer, hyperuricemia/gout, esophageal cancer, breast cancer and other indications.
Currently, there are 10 There are 4 products under research, of which 4 varieties have entered the clinical trial stage
.
Since Haichuang Pharmaceutical started to focus on the deployment of PROTAC technology as early as 2016, the company has also received high attention from the market recently
.
PROTAC stands for Protein Degradation Targeted Chimera, which uses the ubiquitin-proteasome system to induce targeted protein degradation
.
Compared with traditional inhibitors or targeted drugs, PROTACs have the characteristics of fewer adverse reactions, higher targeting and precision, and can prevent mutation-driven drug resistance of enzyme inhibitors
.
At present, PROTAC has become a major new drug outlet after PD-1 inhibitors and CAR-T.
In this field, domestic and foreign companies continue to enter the market, and R&D enthusiasm is high
.
However, there is currently no PROTAC drug approved for marketing in the world, and only a batch of PROTAC drugs are in the clinical or clinical stage
.
Arvinas' ARV-110 is regarded by the industry as the world's first PROTAC drug that is expected to be approved
.
Throughout the country, the number of pharmaceutical companies in the PORTAC field has grown to dozens, including Haisco, Kintor, Hengrui, BeiGene, Haichuang, and CSPC
.
Among them, the leading clinical progress includes Kintor Pharmaceutical, Haisco, BeiGene, and Haichuang Pharmaceutical
.
It is reported that the three PROTAC drugs of Haichuang Pharmaceutical, AR-PROTAC HP518, AR-sv-PROTAC HC-X029 and SHP2-PROTAC HC-X035, are among the top in clinical progress
.
Among them, HP518 is an oral PROTAC drug for the treatment of prostate cancer that degrades AR, and its in vitro biological activity and efficacy are comparable to Arvinas' ARV-110
.
HC-X035 is the world's first PROTAC drug that targets SHP2 degradation independently developed by Haichuang Pharmaceuticals.
It can specifically bind to SHP2 and induce its degradation, inhibit the formation and growth of tumor cells, and thus achieve the purpose of treating tumors
.
The prospectus shows that since its establishment, Haichuang Pharmaceutical has gradually built and improved four core technology platforms including PROTAC targeted protein degradation technology platform and deuterated drug research and development platform
.
The company plans to publicly issue no more than 24.
76 million shares on the Science and Technology Innovation Board.
The funds raised will be used for innovative drug research and development projects, investment in research and development production base construction projects, and development reserve funds
.
According to the "14th Five-Year Plan for Pharmaceutical Industry Development" jointly issued by nine departments of China in January this year, cutting-edge core technologies and drugs including PROTAC targeted protein degradation technology have been incorporated into the plan
.
The industry predicts that with the help of policies, talents, capital, etc.
, Chinese companies are expected to become strong competitors in this track, and companies that deploy in this track in advance are expected to benefit significantly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
